Prevention of colorectal cancer development by Bio-K+ probiotic formula

Bio-K 益生菌配方预防结直肠癌的发生

• 批准号: 418002-2011
• 负责人: Lacroix, Monique
• 金额: $ 5.1万
• 依托单位: Institut national de la recherche scientifique
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=530973
• 关键词: Prevention; colorectal; cancer; development; Bio

Colon cancer is one of the leading causes of morbidity and mortality, not only in Western industrialized countries but also in developed Asian countries. Currently, colorectal cancer (CRC) is the 2nd leading cause of cancer death in Canada (after lung cancer). The most recent estimated statistics for CRC for 2009 are: 22,000 new cases and 9,100 deaths. Estimated CRC deaths in Canada in 2009 are 9,100 (Canadian Cancer Society). Therefore, prevention of cancer in generally and colon cancer in specifically is very important. The use of probiotic bacteria in cancer chemoprevention is an active preventive strategy to inhibit, delay or reverse human carcinogenesis. Some studies have proposed that microbial cell wall components from probiotic bacteria (ex: bacterial peptidoglycans) could be responsible of cancer prevention. However, no study have been done to confirm this hypothesis and to elucidate their mechanisms in cancer prevention. In an in vitro anti-proliferative test against colon cancer cell line, it was found that there was a synergistic effect of Bio-K+® bacterial strains with 5-Fluorouracil in enhancing the apoptosis in a colon cancer cell line. In another research on in vivo prevention of aberrant crypt foci (ACF) formation in rats treated with a carcinogen, Bio-K+® fermented milk was demonstrated to be able to reduce significantly the formation of ACF (a precancerous lesion in rat intestine and related to colon cancer). Based on our recent research, we suppose that BioK+® fermented milk at an optimized dose will have a strong in vivo activity in prevention of aberrant crypt foci (ACF) formation in rats treated with a carcinogenic agent. It is also supposed that bioactive components produced by probiotic strains during milk fermentation to produce Bio-K+® products may be the main components in reduction of ACF formation in rats. The objectives of this work are 1) to investigate the dose-effects of BioK+® fermented milk in reducing precancerous lesions in in vivo test and 2) to fractionate bioactive compounds from BioK+® fermented milk and evaluate their effects in reducing precancerous lesions in in vivo test.

结肠癌不仅在西方工业化国家而且在亚洲发达国家都是发病和死亡的主要原因之一。目前，结直肠癌（CRC）是加拿大癌症死亡的第二大原因（仅次于肺癌）。 2009 年 CRC 的最新估计统计数据为：新增病例 22,000 例，死亡 9,100 例。加拿大癌症协会估计 2009 年加拿大 CRC 死亡人数为 9,100 人。因此，预防一般癌症和特别是结肠癌非常重要。益生菌在癌症化学预防中的应用是抑制、延缓或逆转人类癌症发生的积极预防策略。 一些研究提出，益生菌的微生物细胞壁成分（例如：细菌肽聚糖）可能有助于预防癌症。然而，尚未进行任何研究来证实这一假设并阐明其预防癌症的机制。在针对结肠癌细胞系的体外抗增殖试验中，发现Bio-K+®菌株与5-氟尿嘧啶具有协同作用，可增强结肠癌细胞系的凋亡。另一项关于体内预防接受致癌物治疗的大鼠体内异常隐窝病灶 (ACF) 形成的研究表明，Bio-K+® 发酵乳能够显着减少 ACF（大鼠肠道中的一种癌前病变，与结肠癌相关）的形成。根据我们最近的研究，我们认为优化剂量的 BioK+® 发酵乳在预防接受致癌剂治疗的大鼠中异常隐窝病灶 (ACF) 形成方面具有很强的体内活性。据推测，益生菌菌株在牛奶发酵生产Bio-K+®产品过程中产生的生物活性成分可能是减少大鼠ACF形成的主要成分。这项工作的目的是：1) 在体内试验中研究 BioK+® 发酵乳在减少癌前病变方面的剂量效应；2) 从 BioK+® 发酵乳中分离生物活性化合物，并在体内试验中评估其在减少癌前病变方面的效果。